Anti-cancer Foods: Flavonoids
Phase 1 clinical results: excellent tolerability supporting advancement to Phase 2a Phase 1 clinical study DX243-101 was a randomized, double-blind, placebo-controlled trial designed to primarily assess the safety, tolerability, and pharmacokinetic profile of single and multiple ascending subcutaneous doses of DX243
For some patients, a daily injection may fit comfortably into an established routine
Several studies have found that patients taking GLP-1 receptor agonists, including tirzepatide, report reduced alcohol intake and diminished cravings
Tirzepatide, manufactured by Eli Lilly , is different from Semaglutide because it copies two hormones instead of just one: GLP-1 (like Semaglutide), which helps control hunger and blood sugar GIP, which may help your body burn fat more efficiently and improve how it handles insulin This dual-action approach makes Tirzepatide one of the most effective new treatments for weight loss